Article
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood - 15 Mar 2006
Chandra Joya, Tracy Jeannette, Loegering David, Flatten Karen, Verstovsek Srdan, Beran Miloslav, Gorre Mercedes, Estrov Zeev, Donato Nicholas, Talpaz Moshe, Sawyers Charles, Bhalla Kapil, Karp Judith, Sausville Edward, Kaufmann Scott H
Abstract excerpt
The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.